GILEAD SCIENCES, INC.
GILEAD SCIENCES, INC.'s purchase track record
How the stock did after each of GILEAD SCIENCES, INC.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/18/2025 | GILD | $15.00M | +4.4% | +13.7% | +4.6% |
| 12/19/2024 | ASMB | $20.10M | -32.4% | +10.0% | +1.7% |
| 12/18/2024 | XLO | $1.83M | -8.5% | -23.8% | +1.8% |
| 4/2/2024 | GILD | $369K | -4.0% | +19.0% | +9.7% |
| 2/12/2024 | KYTX | $20.02M | -51.1% | -78.2% | +6.4% |
| 1/29/2024 | GILD | $320.00M | -15.8% | +0.5% | +10.9% |
| 6/27/2023 | GILD | $30.44M | +0.3% | +7.2% | +9.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers. Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Xilio Therapeutics appoints Yariv J. Houvras as Chief Medical Officer. Xilio Therapeutics announced that Dr. Yariv J. Houvras, M.D., Ph.D., will serve as its new Chief Medical Officer. The appointment adds experienced clinical leadership to the company as it advances its therapeutic pipeline. This change comes while the stock is trading near the top of its 52‑week range, suggesting market attention to the leadership update.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Kyverna Reports Positive One-Year Data for Miv-cel Trials. Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.
Transaction History
| ASMB | ▲ Buy | Grant | 471,698 | $12.5M | 5/26/2026 | View on chart |
| ASMB | ▲ Buy | Open Market | 2,295,920 | — | 8/8/2025 | View on chart |
| GILD | ▲ Buy | Open Market | 1,363,636 | $15.0M | 2/18/2025 | View on chart |
| ASMB | ▲ Buy | Open Market | 940,499 | $20.1M | 12/19/2024 | View on chart |
| XLO | ▲ Buy | Open Market | 1,759,978 | $1.8M | 12/18/2024 | View on chart |
| GILD | ▲ Buy | Open Market | 179,500 | — | 6/17/2024 | View on chart |
| GILD | ▲ Buy | Open Market | 485,250 | $369K | 4/2/2024 | View on chart |
| KYTX | ▼ Sell | Other | 3,216,119 | — | 2/12/2024 | View on chart |
| KYTX | ▲ Buy | Open Market | 910,000 | $20.0M | 2/12/2024 | View on chart |
| GILD | ▲ Buy | Open Market | 15,238,095 | $320.0M | 1/29/2024 | View on chart |
| GILD | ▲ Buy | Open Market | 1,010,000 | $19.5M | 6/28/2023 | View on chart |
| GILD | ▲ Buy | Open Market | 2,930,870 | $11.0M | 6/27/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Assembly Biosciences to Present Phase 1a ABI-6250 Data at AASLD 2026
Assembly Biosciences announced that it will share Phase 1a safety, tolerability and target engagement results for its liver‑focused candidate ABI‑6250 at the AASLD Liver Meeting 2026. The data will be the first clinical readout for the program and could provide insight into the drug’s early performance. The announcement comes as the stock trades near its recent support level.
Assembly Biosciences to Present Phase 1a ABI-6250 Data at AASLD 2026. Assembly Biosciences announced that it will share Phase 1a safety, tolerability and target engagement results for its liver‑focused candidate ABI‑6250 at the AASLD Liver Meeting 2026. The data will be the first clinical readout for the program and could provide insight into the drug’s early performance. The announcement comes as the stock trades near its recent support level.